Phase 2/3Status unknown

Weight loss medications on exercise capacity in Pulmonary Arterial Hypertension (PAH) patients

Glucagon-like peptide (GLP-1) Agonist for Patients with Overweight or Obesity and Pulmonary Arterial Hypertension (GO-PAH): An Open-Label Multicentre Proof-of-Concept Study

Sponsor

Sydney Local Health District

Enrolment

20 planned

Conditions

Pulmonary arterial hypertension; Obese; Overweight; Pulmonary arterial hypertension Obese Overweight; Metabolic and Endocrine - Other metabolic disorders; Respiratory - Other respiratory disorders / diseases; Diet and Nutrition - Obesity

Interventions

Semaglutide Dose

Ages

adults, older adults

Registry

ACTRN12626001139369

Full record on ANZCTRSource: WHO ICTRP, processed 21 September 2026